NCT07140081: A Research Study to Evaluate BLX-0871 in Healthy Adults

Summary

This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.

Timeline

Start: 2025-09
Primary completion: 2026-04
Completion: 2026-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BLX-0871	Small molecule	—	Oral

Indications

No indication recorded.